

# NOT TO BE MISSED

## A UNIQUE REGULATORY EDUCATIONAL PARTNERSHIP BETWEEN ISCT AND CAT-EMA

CAT-ISCT Joint Workshop: Challenges and Opportunities for the Successful Development and Approval of Advanced Therapy Medicinal Products

Friday September 25, 2015 • 14:15 – 18:45



### ISCT EUROPE 2015 REGIONAL MEETING

September 24-26, 2015  SEVILLE, SPAIN  **Barceló Sevilla Renacimiento**

**ISCT REGIONAL MEETING**  
 SEVILLE • SPAIN • 2015

International Society for Cellular Therapy  
**ISCT**   
Region • Europe

[WWW.ISCT-EU2015.COM](http://WWW.ISCT-EU2015.COM)

# CAT-ISCT Joint Workshop Program

## 14:15 WELCOME FROM WORKSHOP CHAIRS

- Paula Salmikangas, Finnish Medicines Agency (FIMEA) – CAT Chair, Finland
- Natividad Cuende, Executive Director, Andalusian Initiative for Advanced Therapies, Spain

## 14:20 INTRODUCTION

**Moderator: Natividad Cuende**, Executive Director, Andalusian Initiative for Advanced Therapies, Spain

- **Intelligent ATMP Development: Flexibilities and Pitfalls**  
**Speaker: Paula Salmikangas**, Finnish Medicines Agency (FIMEA) – CAT Chair, Finland

## 14:40 QUALITY DEVELOPMENT/MANUFACTURING ISSUES AND NON-CLINICAL TESTING

**Moderator: Dariusz Śladowski**, Medical University of Warsaw – CAT member, Poland

- **Experience from CAT on Quality Development/Manufacturing/GMP**  
**Speaker: Margarida Menezes Ferreira**, Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.(INFARMED) – Alternate CAT member, Portugal
- **Experience from CAT on Non-Clinical Development**  
**Speaker: Tiina Palomäki**, Finnish Medicines Agency (FIMEA) – CAT member, Finland
- **Views from ATMP developer from academia on quality/manufacturing issues encountered during the manufacture of ATMPs for clinical trials**  
**Speaker: Laura Leyva**, Technical Director of the Cell Therapy GMP facility, University Regional Hospital in Málaga, Spain
- Q&A

## 16:10 CLINICAL DEVELOPMENT

**Moderator: Edwin Wagena**, ISCT Europe Regional Vice President, Netherlands

- **Clinical Trials with ATMPs: Experience from CAT**  
**Speaker: Tomáš Boráň**, Státní ústav pro kontrolu léčiv – CAT member, Czech Republic
- **Specificities of Clinical Development of ATMPs: Considerations regarding exploratory and confirmatory trials**  
**Speaker: Martina Schüßler-Lenz**, Paul-Ehrlich-Institute, Germany – CAT member and Vice-Chair, Germany
- **Use of Retrospective Studies for Marketing Authorization**  
**Speaker: Giovanni Milazzo**, Chiesi Farmaceutici, Head Regulatory Affairs Advanced Medicines, Italy
- **The New Clinical Trial Regulation: What will change for ATMP developers**  
**Speaker: Simona Badoi**, Agentia Națională a Medicamentului și a Dispozitivelor Medicale – CAT member, Romania
- Q&A

## 17:50 SUPPORT FROM EMA/CAT TO ATMP DEVELOPERS

**Moderator: Paula Salmikangas**, Finnish Medicines Agency (FIMEA) – CAT Chair, Finland

- **Presentation on support available to ATMP developers and approval mechanism (adaptive pathways, conditional approval, approval under exceptional circumstances)**  
**Speaker: Patrick Celis**, European Medicines Agency, CAT Scientific Secretariat, UK

## 18:15 OPEN FORUM/PANEL DISCUSSION

## 18:45 CLOSING REMARKS